Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

Rhea-AI Summary

Molecular Templates, Inc. (Nasdaq: MTEM) announced CEO Eric Poma, Ph.D., will participate in two upcoming conferences from November 29 to December 1, 2022. The first event is a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference on November 30 at 9:15 AM ET, focusing on positive data regarding next-generation engineered toxin bodies (ETBs). The second is an in-person chat at Piper Sandler’s 34th Annual Healthcare Conference on December 1 at 3:00 PM ET in New York. Attendees can access both events via registration links provided by the company.

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5^th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler’s 34^th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022. Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs. One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.

Evercore ISI 5^th Annual HealthCONx Conference

• Format: Virtual Fireside Chat
• Time/Date: 9:15am ET, Wednesday November 30, 2022
• Access: Webcast and archive are available via the “Events” section of MTEM’s website or by registering to join here
  

Piper Sandler 34^th Annual Healthcare Conference

• Format: In-person Fireside Chat with Analyst Q&A
• Location: Lotte NY Palace Hotel – Spellman, 5^th Fl
• Time/Date: 3:00pm ET, Thursday December 1, 2022
• Access: In-person attendance is open for conference registrants, and the webcast/archive is available via the “Events” section of MTEM’s website or by registering to join here

About Molecular Templates

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “potential,” “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates, including the anticipated benefits of MT-6402, MT-5111, MT-0169, and MT-8421 and Molecular Templates’ next-generation ETBs; statements relating to the development of MT-6402, MT-5111, MT-0169, MT-8421 and next-generation ETBs; the expected timing for submitting various IND applications and conducting studies, opening sites and generating data; the expected participation and presentation at upcoming conferences; the expected timing for providing updates on MT-6402, MT-5111, MT-0169, and MT-8421, as well as Molecular Templates’ earlier stage pipeline of ETBs, including any pre-clinical data; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer and other serious diseases.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether Molecular Templates’ cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contact:

Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com

FAQ

What is Molecular Templates' upcoming presentation schedule?

Molecular Templates will have a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference on November 30, 2022, and an in-person chat at Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022.

What will be discussed during the Molecular Templates fireside chats?

The fireside chats will review positive incremental data on Molecular Templates’ next-generation engineered toxin bodies (ETBs) and related programs.

When is the virtual fireside chat scheduled for Molecular Templates?

The virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference is scheduled for November 30, 2022, at 9:15 AM ET.

Where is the Piper Sandler Healthcare Conference being held?

The Piper Sandler 34th Annual Healthcare Conference will be held at the Lotte NY Palace Hotel in New York City.

How can I access Molecular Templates' conference presentations?

Interested parties can access the webcasts and archives of the presentations through the 'Events' section of MTEM’s website or via the provided registration links.

What is the focus of Molecular Templates as a biopharmaceutical company?

Molecular Templates focuses on the discovery and development of targeted biologic therapeutics, utilizing engineered toxin bodies (ETBs) for treating cancer and serious diseases.